Groowe Groowe / Newsroom / JNJ
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

JNJ News

Johnson & Johnson

Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research

prnewswire.com
TMO MRK BIO BIIB AMGN GILD REGN CRSP NTLA BMY ABBV AZN NVS PFE JNJ MRNA BNTX COR STEM ALGN EXAS MDLZ BHC CVS UNH CI CNC ELAN ZTS ISRG QRVO SWKS AVGO QCOM INTC MSFT GOOG AMZN IBM ORCL CRM ADBE NFLX DIS MCD SBUX KO PEP PG JPM BAC WFC C GS MS AXP V MA HD LOW COST TGT WMT BBY CMCSA VZ T XOM CVX SIRI UBER LYFT NVDA AMD MU AMAT LRCX ASML ADI TXN QGEN ILMN VRTX EDIT BEAM SRPT ACAD ALKS MDT SYK DHR GOOGL

U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs

globenewswire.com
BMY GILD JNJ SNY TAK AMGN AZN LLY MRK PFE REGN VRTX ABBV ALNY AMTX BIIB BMRN CRSP EXAS INCY IONS JAZZ NTLA PTC RGEN XOM

Conjunctivitis Market to Reach $61.6 Billion by 2033 Globally, at 13.8% CAGR: Allied Market Research

prnewswire.com
ABBV JNJ BHC NVS

Genmab Publishes 2025 Annual Report

globenewswire.com
GMAB HALO ABBV MRUS NVS JNJ HRZN

Intraocular Lens Market Poised for Strong Growth as Rising Cataract Procedures and Premium Vision Correction Demand Accelerate: Verified Market Research®

prnewswire.com
ALC BHC JNJ SGA ABT

Stella Mental Health Expands Boston-Area Services with New Newton Clinic as Chief Psychiatric Officer Dr. Brian Boyle Selected as 2026 National SPRAVATO® Bureau Speaker

prnewswire.com
JNJ

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

globenewswire.com
SUPN MGTX JNJ ARWR

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

prnewswire.com
JNJ

CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™

prnewswire.com
BMY GILD JNJ CRSP ALLO CART

Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer

prnewswire.com
JNJ PFE